Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Erlotinib (Primary) ; Tipifarnib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 17 May 2018 Status changed from active, no longer recruiting to completed.
- 10 Jan 2014 Planned End Date changed to 1 May 2008 as the status is active, no longer recruiting as reported in ClinicalTrials.gov record.
- 29 Dec 2006 Status change